Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial ...
Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.
Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback